Roche partners with Chinese startup Defand Therapeutics for new drug discovery
Roche announced a partnership with Chinese biotech firm Defand Therapeutics to discover new medicines rather than just licensing existing candidates.
Shift from licensing to discovery
Pharma companies have recently focused on licensing drug candidates from China. Roche is changing this approach by collaborating with a startup to find new treatments. This move marks a different strategy than the usual licensing deals seen in recent years.
Focus on early stage research
The agreement allows Roche to work directly with Defand Therapeutics on developing novel therapies. This collaboration aims to expand their pipeline through early-stage discovery processes. The partnership represents a broader trend of international cooperation in biotechnology.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.